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Poly(ADP-ribose) polymerases (PARPs) are DNA-dependent nuclear enzymes that transfer
negatively charged ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide
(NAD+) to a variety of protein substrates, altering protein–protein and protein-DNA inter-
actions. The most studied of these enzymes is poly(ADP-ribose) polymerase-1 (PARP-1),
which is an excellent therapeutic target in cancer due to its pivotal role in the DNA dam-
age response. Clinical studies have shown susceptibility to PARP inhibitors in DNA repair
defective cancers with only mild adverse side effects. Interestingly, additional studies are
emerging which demonstrate a role for this therapy in DNA repair proficient tumors through
a variety of mechanisms. In this review, we will discuss additional functions of PARP-1 –
including regulation of inflammatory mediators, cellular energetics and death pathways,
gene transcription, sex hormone- and ERK-mediated signaling, and mitosis – and the role
these PARP-1-mediated processes play in oncogenesis, cancer progression, and the devel-
opment of therapeutic resistance. As PARP-1 can act in both a pro- and anti-tumor manner
depending on the context, it is important to consider the global effects of this protein in
determining when, and how, to best use PARP inhibitors in anticancer therapy.
Keywords: PARP-1, PARP inhibitors, NF-κB, genetic transcription, sex hormone signaling, ERK signaling, angiogen-
esis, mitotic spindle
INTRODUCTION
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme
which binds DNA via two zinc finger motifs and transfers chains
of ADP-ribosyl moieties (PARs) from nicotinamide-adenine-
dinucleotide (NAD+) to chromatin-associated acceptor proteins,
including PARP-1 itself. This post-translational modification plays
an important role in promoting DNA repair by releasing PARP-
1 from DNA and allowing for recruitment of proteins involved
in both base excisional repair (BER) and homologous recombi-
nation (HR) (1). Accordingly, PARP-1 is an attractive anticancer
target, and poly(ADP-ribose) polymerase (PARP) inhibitors have
been identified as chemo- and radiation-sensitizing agents in an
array of cancers (2–5), including our report on the sensitization
of head and neck cancer to radiotherapy following PARP inhibi-
tion (6). Perhaps the most well-known tumoricidal effects of PARP
inhibitors are in BRCA-mutated cancers,which harbor DNA repair
defects and become dependent on PARP-1-mediated repair for
survival. Two landmark studies (7, 8) found inhibition of PARP-1
in cells containing BRCA mutations resulted in the generation of
chromatid breaks, G2 cell cycle arrest, and enhancement of apop-
tosis, results which have been confirmed in early phase clinical
trials (9, 10).
Interestingly, recent studies also show potential efficacy of PARP
inhibition in sporadic tumors lacking DNA repair defects. A clin-
ical study of the PARP inhibitor olaparib in women with heavily
pretreated high-grade serous ovarian cancer without germline
BRCA1/2 mutations resulted in objective responses in 11/46 (24%)
(11), indicating there may be additional determinants of sen-
sitivity to PARP inhibition. Pre-clinical studies have identified
susceptibility to PARP inhibition alone in HR-proficient HER2-
positive breast cancer, pancreatic cancer, prostate cancer, Ewing’s
sarcoma, small cell lung carcinoma, and neuroblastoma, among
others (12–17). These reports demonstrate the existence of non-
DNA repair functions of PARP-1 that may be targetable for cancer
treatment. It is thus becoming increasingly apparent that a num-
ber of PARP-1-mediated cellular processes influence characteris-
tics of tumor development, progression, and treatment response,
including several of the eight “hallmarks of cancer” proposed by
Hanahan and Weinberg (18) (Figure 1). In this review, we will dis-
cuss cancer-related functions of PARP-1 – including regulation of
inflammatory mediators through NF-κB, cell death and energet-
ics, ERK-mediated tumor progression and invasion, mitosis, gene
transcription, and sex hormone signaling – and examples of how
these functions may be exploited to expand the patient population
potentially benefiting from treatment with PARP inhibitors.
NF-κB-MEDIATED TUMOR-PROMOTING INFLAMMATION
In multiple cancers, including breast, prostate, and head and neck
among others, the NF-κB signaling pathway undergoes a loss of
regulation resulting in constitutive activation (19). Briefly, NF-κB
is a family of transcription factors including RelA/p65, RelB, c-Rel,
p50, and p52, which exist as homo- and hetero-dimers. DNA-
binding affinity and DNA sequence specificity is dependent on the
composition of the dimer. Inhibitory proteins bind NF-κB dimers
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FIGURE 1 | Non-DNA repair functions of PARP-1 influence the “hallmarks
of cancer” (18). This schematic depicts multiple PARP-1-mediated processes
which either stimulate or inhibit six of the eight “hallmarks of cancer,” as
indicated by green and red boxes respectively. These hallmarks, proposed by
Hanahan and Weinberg, are malignant characteristics that provide a
framework for understanding the biology of cancer.
and sequester them in the cytosol in the absence of a stimulus;
pathway activation causes proteasomal degradation of inhibitors,
allowing the dimer to translocate to the nucleus and activate pro-
inflammatory transcription programs. Although NF-κB signaling
mediates the acute immune response responsible for targeting
and eliminating cancerous cells, chronic inflammation mediated
by this “hallmark” pathway can lead to the malignant phenotype
(Figure 1), facilitating escape from immune surveillance, cancer
survival, metastasis, and angiogenesis (20).
Activation of NF-κB can be regulated by PARP-1 via multiple
mechanisms (Figure 2). First, PARP-1 directly interacts with his-
tone acetyl-transferases p300 and CREB-binding protein (CBP)
to synergistically co-activate NF-κB-dependent gene expression.
In response to inflammatory stimuli, p300/CBP acetylates PARP-
1 at specific lysine residues. This modification is necessary for
PARP-1-p50 interaction, enhancement of p300–p50 interaction,
and co-activation of NF-κB-mediated transcription programs (21,
22). Co-activation is negatively regulated by the activity of class
I histone deacetylases (HDACs) (22) and SUMO1/3-mediated
SUMOylation of the automodification domain of PARP-1 (23).
Second, enzymatic activation of PARP-1 variably affects NF-κB,
with outcomes dependent on the identity of the PAR acceptor
protein. AutoPARylation of PARP-1 following detection of DNA
strand breaks promotes the formation of a “signalosome” contain-
ing IKKγ (NEMO), the regulatory subunit of a NF-κB inhibitory
complex, along with PIASγ, and ATM. Chains of PAR on activated
PARP-1 provide the scaffold needed for SUMOylation of IKKγ
by the PIASγ PAR binding motif, leading to activation of IKK
and NF-κB (24). The effects of PARylation on NF-κB itself are
less clear, with different sources reporting decreased, increased, or
unaffected DNA-binding activity (25–27). Taken together, these
studies demonstrate a strong role for PARP-1 in regulating NF-κB
activity.
The interaction between PARP-1 and the NF-κB pathway pro-
motes production of pro-inflammatory cytokines such as TNFα,
IL-6, INFγ, E-selectin, and ICAM-1, as well as expression of nitric
oxide synthase (28–30); PARP inhibition has been shown to atten-
uate upregulation of these factors in response to inflammatory
stimuli (28, 29). Furthermore, PARP inhibition may also pre-
vent inflammation-associated adverse side effects of traditional
chemotherapeutics (31), supporting the use of PARP inhibitors in
multidrug regimens. Loss of PARP-1 activity not only decreases
pro-tumor inflammation, but also inhibits two related hallmarks
of cancer through anti-inflammatory mechanisms: proliferative
signaling (32) and metastasis (33, 34) (Figure 1).
Recently, we discovered an unexpected sensitivity to PARP inhi-
bition in DNA repair proficient HER2-positive breast cancer cells
through attenuation of NF-κB-mediated signaling (13). HER2
over-expressing cancers have activated NF-κB, which acts to block
apoptosis and possibly mediate resistance to HER2-targeted drugs
(35). In HER2-positive breast cancer cells, treatment with PARP
inhibitor significantly reduced the expression of NF-κB activator
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FIGURE 2 | Poly(ADP-ribose) polymerase-1 mediates activation of
NF-κB signaling. (Left) inflammatory stimulation triggers p300/CBP
acetylation of PARP-1, enhancing the interaction between p50 and PARP-1
as well as the p50–p300 interaction; this ultimately leads to activation of
NF-κB. (Right) DNA damage detection promotes the formation of a complex
including PARP-1, ATM, PIASγ, and IKKγ (NEMO); chains of PAR on PARP-1
provide a structure upon which PIASγ SUMOylates IKKγ, leading to NF-κB
activation.
IKKα and phosphorylated p65 while increasing inhibitory IkBα.
These events resulted in decreased NF-κB transcriptional activity
in HER2-positive, but not HER2-negative, breast cancer cells (13).
Furthermore, overexpression of HER2 alone was sufficient to con-
fer sensitivity to PARP inhibitor, suggesting synthetic lethality with
PARP inhibition in tumors that are oncogene-addicted to HER2
signaling through NF-κB. This study represents a specific applica-
tion of PARP-1-regulated NF-κB signaling to cancer therapy, one
that may soon be expanded into a clinical trial.
CELLULAR ENERGETICS AND CELL DEATH
Cancer cells are characterized by excessive proliferation, impaired
cell death signaling, and deregulated metabolism (Figure 1). These
features are often mediated by altered mitochondrial activity cou-
pled with inactivation of apoptotic signaling through decreased
expression of pro-apoptotic factors like p53 or overexpression of
anti-apoptotic factors like Bcl-x. Integrity of regulatory pathways
for cell death and metabolism is important for response to many
cancer treatment modalities, as well as in cancer imaging and
diagnostics. Cellular energetics and death signaling are heavily
regulated by PARP-1, allowing activity of this protein to serve as
a switch between cell fates and to affect both tumor proliferation
and therapeutic response.
In response to damage stimuli, activated PARP-1 acts early in
the apoptosis initiation pathway to stabilize p53 and facilitate its
function (36). If damage is excessive, high levels of PAR synthe-
sis by PARP-1 deplete its NAD+ substrate; additional interactions
between PARP-1 and NMNAT-1, a NAD+ synthase, and SIRT1,
a NAD+-dependent protein deacetylase, further contribute to
PARP-1 as a controller of NAD+ availability and, thus, NAD-
dependent metabolic reactions. ATP-dependent NAD+ salvage
saps cellular ATP stores, resulting in energy deprivation and, even-
tually, energy crisis-induced necrosis (Figure 3). Furthermore,
PARP-1-mediated PARylation may inactivate caspase-8 and reduce
caspase-mediated apoptotic signaling (37). Hyperactivation of
PARP-1 and accumulation of PAR can also cause translocation of
PAR to the cytosol, where it interacts with the outer mitochondrial
surface. Here it binds apoptosis inducing factor (AIF) and induces
its release and translocation to the nucleus, ultimately resulting
in large-scale DNA fragmentation and a novel PARP-1-dependent
cell death mechanism known as “parthanatos” (38). To prevent
these events, activated caspases cleave PARP-1 into two fragments:
an 89-kDa C-terminal fragment with low levels of catalytic activ-
ity and a 24-kDa N-terminal peptide which inhibits the catalytic
activity of uncleaved nuclear PARP-1. Conservation of NAD+ and,
thus, ATP allows the cell to undergo programed cell death (39–41).
Accordingly, inhibition of PARP-1 preserves ATP levels, improves
antioxidant status, and normalizes anti-apoptotic Bcl-x levels in
the kidney following chemotherapy-induced injury (42, 43).
Poly(ADP-ribose) polymerase-1 also regulates the classical
necroptotic pathway mediated by the death promoting MAP
kinase, c-Jun N-terminal kinase (JNK). This signaling network
is activated in many cancers and has been implicated as a dri-
ver of both tumor development and treatment response (44, 45).
PARP-1 downregulates MAP kinase phosphatase MKP-1 expres-
sion and inhibits the survival kinase Akt, both of which activate
JNK (46, 47), suggesting potential benefit for PARP inhibition in
tumors with elevated JNK activity. JNK1 mediates phosphoryla-
tion and sustained activation of PARP-1, creating a feed-forward
regulatory loop (48). In conjunction, PARP-1-induced depletion
of ATP stimulates AMP-activated protein kinase (AMPK) while
inhibiting mTOR to promote autophagy, yet another cell death
pathway important in cancer survival and treatment response (49).
Pharmacologic inhibition of PARP-1 promotes Akt activity and
mTOR signaling resulting in decreased cell death (50), although
these results are contradicted by a recent report showing PHLPP1-
mediated downregulation of Akt activity and increased cell death
following PARP inhibition (51).
Clinically, targeting the role of PARP-1 in cell death pathways
appears to be complex. PARP-1 inhibition may reduce PAR-
mediated inactivation of caspase-8, sensitizing cancer cells to
tumor necrosis factor-related apoptosis-induced ligand (TRAIL)
therapy (37). Additionally, inhibition of PARP-1 prevented
cisplatin- and methotrexate-induced ATP depletion and nephro-
toxicity (42, 43), as well as imatinib (Gleevec)-induced JNK
activation and cardiotoxicity (52), without significantly affect-
ing the anticancer activity of these agents. However, activation
of the Akt survival pathway may counteract the cytotoxic effects
of PARP inhibition and cause resistance to therapy (47), sug-
gesting Akt pathway inhibition may enhance PARP inhibition in
anti-tumor therapy. Despite these complexities, the influence of
PARP-1 on metabolic co-factors and cell death signaling is signif-
icant, and further studies examining the role of PARP inhibition
in manipulating these processes is warranted.
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FIGURE 3 | Poly(ADP-ribose) polymerase-1 acts as a switch between cell
fates. Hyperactivation of PARP-1 and PAR synthesis depletes NAD and,
subsequently, ATP. Elevated PAR can promote necrosis, autophagy, or
AIF-induced parthanatos. In addition, PARylation inactivates caspase-8,
inhibiting apoptotic signaling. Alternatively, activated caspases can cleave
PARP-1; the resulting cleavage product inhibits uncleaved PARP-1, conserving
NAD/ATP, and promoting apoptosis. These cell death pathways play a role in
both cancer survival and response to anticancer therapy.
ERK-MEDIATED ANGIOGENESIS AND METASTASIS
In addition to the JNK-mediated signaling described previously,
a second family of MAP kinases known as extracellular signal-
regulated kinases or ERKs is involved not only in cell death
determination but also in tumor progression, angiogenesis, and
metastasis. ERK activation is pivotal in cancer cell survival through
upregulation of anti-apoptotic proteins and inhibition of caspase
activity (53). Inhibition of this pathway by targeting ERK or MEK,
which is immediately upstream of ERK in signaling, has been asso-
ciated with suppression of ovarian tumor growth (54), reduced
metastatic potential of melanoma cells (55), and increased sensi-
tivity to cytotoxic agents (56). Recent studies indicate an important
role for PARP-1 in promoting ERK signaling.
Poly(ADP-ribose) polymerase-1 is activated and autoPARy-
lated by a direct interaction with phosphorylated ERK2 (pERK2),
resulting in enhanced pERK2-catalyzed phosphorylation of tar-
get transcription factors and increased gene expression (57).
Furthermore, PARP inhibition causes loss of ERK2 stimulation by
decreasing the activity of critical pro-angiogenic factors includ-
ing vascular endothelial growth factor (VEGF), transmembrane
signaling protein syndecan-4 (SDC-4), platelet/endothelial cell
adhesion molecule (PECAM1/CD31), and hypoxia inducible fac-
tor (HIF). This ultimately results in reduced angiogenesis and
inflammation (58–62). The effects of PARP-1 on ERK signaling are
further enhanced by PARP-1-mediated transcription of vimentin,
an intermediary angiogenic filament upregulated in tumor
vasculature and pivotal for the endothelial-to-mesenchymal
transition characteristic of metastasis (63). Pharmacologic inhibi-
tion of PARP reverted this transition, correlating with a reduction
in the number and size of metastatic melanoma foci in a mouse
model (63).
Collectively, these studies indicate PARP-1 directly fosters ERK
signaling in addition to mediating separate but parallel signaling
pathways reinforcing the same end result of increased angiogen-
esis and metastasis, two tumor-promoting features (Figure 1). As
such, PARP inhibition may be effective in blocking the ERK signal-
ing network or increasing activity of ERK/MEK inhibitors, agents
already shown to be efficacious in acute myeloid leukemia, mul-
tiple myeloma, melanoma, colorectal, breast, lung, and pancreatic
cancers (64–68). Furthermore, selective ERK inhibition induces
tumor regression in MEK inhibitor-resistant models (67), raising
the question of whether PARP inhibition could be similarly effec-
tive in either MEK or ERK-resistant tumors due to its proximity
in the signaling pathway. As MEK, ERK, and PARP inhibitors have
only recently entered early phase clinical trials, it will be some time
before we know which patients benefit most from these drugs,
either alone or in combination, but their interaction warrants
further investigation.
MITOTIC REGULATION
The high proliferation rate of cancer cells is a result not only of
decreased cell death but also of improperly regulated cell cycling,
allowing evasion of growth suppressing signals. Although multi-
ple cell cycle checkpoints can be impaired in cancer, the mitotic
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or spindle assembly checkpoint is of great importance both in
tumorigenesis and as an anticancer target. This point of regula-
tion, which is responsible for ensuring appropriate chromosome
segregation, is required for cell viability. Cells with a weakened
mitotic checkpoint are capable of survival but do not maintain
proper chromosome segregation, resulting in genomic instability
and aneuploidy. These are common features of tumor cells and
may even act as drivers in cancer development (Figure 1). PARP-
1 can act on many mediators of cell cycle progression through
its effects on gene expression (68), which will be detailed in a
later section. However, direct regulation of the mitotic checkpoint
by PARP-1 is another important factor that may be targetable in
cancer treatment.
Recent reports suggest multiple roles for PARP-1 in the struc-
tural machinery of mitosis. First, PAR, which is primarily syn-
thesized by PARP-1, is required for assembly and function of
the bipolar spindle (69). In addition, PARP-1 both localizes to
and PARylates proteins at centromeres and centrosomes dur-
ing mitosis (70, 71). PARP-1 also mediates PARylation of p53,
which is responsible for regulating centrosome duplication and
monitoring chromosomal stability (71). Loss of PARP-1activity
is associated with mislocalization of centromeric and centroso-
mal proteins, resulting in incomplete synapsis of homologous
chromosomes, defective chromatin modifications, and failure to
maintain metaphase arrest, indicating loss of mitotic checkpoint
integrity (71, 72). Similarly, inhibition of PARP-1 is associated
with genomic instability characterized by reduced stringency of
mitotic checkpoints, centrosome hyperamplification, and chro-
mosomal aneuploidy, the most common characteristic of solid
tumors (71, 73, 74).
Furthermore, PARP-1 has been shown to interact with the E3
ubiquitin ligase, CHFR, a tumor suppressor with an important
role in the early mitotic checkpoint. Binding of these two pro-
teins results in degradation of PARP-1 and cell cycle arrest in
prophase, an effect stimulated by the microtubule inhibitor doc-
etaxel resulting in resistance to this drug in CHFR-over-expressing
cancer cells. Concomitant use of a PARP inhibitor with docetaxel
significantly increased apoptosis in these cells, suggesting a role for
PARP inhibition in sensitizing cancers with high CHFR activity to
microtubule inhibitors (75).
GENE TRANSCRIPTION
The clinical characteristics of cancer, including growth, metasta-
tic potential, and response to treatment, are greatly influenced by
dysregulation of gene transcription. Gene expression profiles are
currently being utilized as tumor biomarkers, indicators of treat-
ment sensitivity or resistance, and prognostic predictors. In the
future, there may even be a role for therapeutic agents that reacti-
vate a silenced tumor suppressor or silence an activated oncogene.
In total, 3.5% of the transcriptome is regulated by PARP-1 with 60–
70% positively regulated (76), including genes involved in tumor
promotion such as JUND, MDM2, HGF, FLT1 (VEGFR1), EGFR,
HIF2A (EPAS1),SPP1 (OPN),MMP28,ANGPT2, and PDGF (77).
As discussed below and shown in Figure 4, this regulation can
occur broadly through interactions with nucleosomes and mod-
ification of chromatin, can be gene specific through interactions
with promoters and binding factors, or can result as a combination
of the two, as binding of PARP-1 to nucleosomes mediates its
localization to specific target gene promoters (78, 79).
CHROMATIN STRUCTURE
One mechanism by which PARP-1 alters gene expression is
through regulation of chromatin structure and, thus, DNA acces-
sibility. Simultaneous binding of multiple neighboring nucleo-
somes by PARP-1 compacts chromatin into a supranucleoso-
mal structure, repressing gene transcription (79). This structural
change is further stimulated by histone deacetylation mediated
by a complex consisting of PARP-1, ATP-dependent helicase Brg1
(SmarcA4), and HDACs (80). Conversely, PARylation of core his-
tones promotes charge repulsion-induced relaxation of chromatin
and recruitment of transcription machinery (81–83). PARP-1-
mediated PARylation also results in disassociation of linker histone
H1, a repressor of RNA polymerase II-mediated transcription;
accordingly, higher proportions of PARP-1:H1 indicate active
promoters (84), suggesting potential utility of PARP-1 as a bio-
marker for actively transcribed genes. Although these outcomes
can be separated by PARP-1 activity (protein binding versus
enzymatic function), pharmacologic inhibition of PARP affect
both actions, indicating manipulation of chromatin accessibility
through PARP-1 is not currently an option for cancer therapy.
METHYLATION PATTERNS
Along with chromatin structure, methylation patterns also play a
large role in determining DNA accessibility. Alterations in DNA
methylation are commonly found in many cancers and serve as
a functional equivalent to a gene mutation in the process of
tumorigenesis. Inhibition of PARP-1 is associated with transcrip-
tional silencing through accumulation of DNA methylation and
CpG island hypermethylation throughout the genome (85). This
effect may be mediated by dimerization of PARP-1 with CCCTC-
binding factor (CTCF), a chromatin insulator which binds to
hypomethylated DNA regions. As the CTCF-PARP-1 interaction is
PAR-dependent, decreased PAR following PARP inhibition abro-
gates this function (86, 87). Loss of CTCF-PARP-1 complex activ-
ity results in transcriptional silencing of multiple loci including
tumor suppressors CDKN2A-INK4 (p16), CDH1 (e-cadherin),
and P19ARF (88, 89).
Poly(ADP-ribose) polymerase-1 can also hinder DNA methy-
lation by dimerization with DNA (cytosine-5-)-methyltransferase
1 (DNMT1), a methyltransferase found overexpressed in gastroin-
testinal tract carcinomas, resulting in inhibition of its methyltrans-
ferase activity (85, 90). In contrast, PARP-1 binding and PARyla-
tion of the Dnmt1 promoter actually enhances its transcription
by preventing methylation-induced silencing (91). The reduced
catalytic efficiency of PARylated DNMT1 may come as a result
of negatively charged PARylated PARP-1 out-competing DNA for
binding with DNMT1 (92). Interestingly, PARP-1-DNMT1 can
form a ternary complex with CTCF at unmethylated CTCF-target
sites in a PAR-dependent manner. Loss of PAR from this complex
causes dissociation of PARP-1 and CTCF, allowing the still-bound
DNMT1 to methylate the site and inhibit transcription (92).
Although some specific tumor suppressors are mentioned
above as being affected by PARP-1-mediated chromatin insulation,
the activity of PARP-1 in regulating DNA methylation patterns
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FIGURE 4 | Poly(ADP-ribose) polymerase-1-regulates gene transcription
through multiple mechanisms. [1] PARP-1 binds neighboring nucleosomes
resulting in chromatin compaction. [2] PARP-1 PARylation of core histones
mediates chromatin relaxation. [3] PARP-1 promotes hypomethylation of DNA
by enhancing the chromatin insulator activity of CCCTC-binding factor (CTCF)
while inhibiting methyltransferase activity of DNMT1. [4] PARP-1 promotes
loading and retention of RNA polymerase II at active promoters. [5] PARP-1
binds regulatory DNA sequences and transcription factors, PARylates
transcription factors, and recruits additional regulatory binding proteins in a
target gene specific manner.
at specific genes or genic regions is largely unknown. As such,
it is difficult to predict the effect of PARP inhibition on cancer
growth and progression through this mechanism. However, with
the advent of genomic profiling, it has recently become possible
to identify methylation changes specific to certain cancer sub-
types. Anticancer agents with epigenetic modifying activity, such as
DNA methyltransferase inhibitors, are being investigated in these
cancers and show promising results, especially in hematologic
malignancies (93). The effect of PARP inhibition on epimutations
has not been studied, but the reports described above suggest PARP
inhibitors could have similar applicability.
RNA POLYMERASE II ACTIVITY
Poly(ADP-ribose) polymerase-1 can also promote transcription
in a more sequence-specific manner by positively regulating RNA
polymerase II activity at active promoters. This occurs through: (1)
PARylation-induced exclusion of histone demethylase KDM5B,
maintaining levels of activating histone mark K3K4me3 (82), (2)
PARylation-induced dissociation of the DEK repressor, promoting
loading of the RNA polymerase II mediator complex (94), and (3)
creation of a PAR scaffold for retention of RNA polymerase II (95).
Surprisingly, a recent report showed that inhibition of PARP-1
enzymatic activity was associated with increased H3K4me3, result-
ing in upregulation of sodium iodide symporter transcription and
elevated radio-iodine uptake in thyroid cancer cell lines (96). This
contradictory work may result from target gene specific functions
of PARP-1, as the previously cited studies were focused on genes
known to be positively regulated by PARP-1. However, it does illus-
trate the need for greater understanding of PARP-1 involvement
at active gene promoters, as well as the potential for manipulat-
ing PARP-1-mediated transcription to enhance efficacy of cancer
therapy.
DNA AND TRANSCRIPTION FACTOR BINDING
Gene expression can be further regulated by direct interactions
between PARP-1 and DNA elements or binding factors. PARP-1
acts as a promoter-specific switch at target genes, facilitating the
release of inhibitory co-regulators and recruitment of stimulatory
co-regulators (97, 98). PARP-1 binding of the NF-κB immediate
upstream region (IUR) element activates transcription of CXCL1,
which encodes melanoma growth stimulatory activity protein and
is overexpressed in the progression of malignant melanoma (99).
Binding of PARP-1 to the transcription factor E2F-1 increases
E2F-1 promoter activity and expression of the E2F-1-responsive
oncogene Myc (c-Myc) (100). PARP-1 expression and activity are
also required for cancer cell invasion (Figure 1) mediated by ETS
transcription factors – whose fusion products drive Ewing’s sar-
coma, acute myeloid leukemia, and prostate cancer – and the
Ewing’s sarcoma fusion protein EWS-FLI (14, 15). While PARP-
1 interaction with these factors promotes pro-tumor signaling,
other interactions have the opposite effect. PARP-1 suppresses self-
inhibition of AP-2, a transcription factor that negatively regulates
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Table 1 | Summary of reported non-DNA repair functions of PARP-1 with potential clinical correlations.
PARP-1 function Effect Model system studied Clinical applicability of PARP inhibition
Binding histone
acetyl-transferases p300/CBP
Co-activation of NF-κB
(pro-inflammatory)
In vitro and in vivo HER2+
breast cancer cell lines
May inhibit cancer metastasis; cytotoxicity in
HER2-positive breast cancer specifically (13, 21, 22)
Binding DNMT1 Enhances Dnmt1
transcription, inhibits
methyltransferase activity
In vitro mouse fibroblasts May have activity in DNMT1-overexpressing
colorectal, gastric, and hepatic carcinomas (85,
91, 92)
Binding pERK2 Promotes target gene
transcription
In vitro endothelial cells May inhibit cancer growth and metastasis (58)
Binding CHFR Prophase arrest, resistance to
microtubule inhibitors
In vitro gastric carcinoma cell
lines
Re-sensitizes CHFR-expressing cancers to
microtubule inhibitor therapy (75)
Downregulation of MKP-1 and
inhibition of Akt
Activation of JNK In vitro hepatocytes May have activity in tumors with high JNK activity
(46, 47)
AutoPARylation Activation of NF-κB
(pro-inflammatory)
In vitro and in vivo HER2+
breast cancer cell lines
May inhibit cancer metastasis; cytotoxicity in
HER2-positive breast cancer specifically (13)
Caspase-8 PARylation Impaired apoptotic signaling In vitro and in vivo pancreatic
cancer cell lines
Sensitizes cancer cells to TRAIL therapy (37)
PARylation ATP depletion, promotes
necrosis and autophagy
Mouse and rat kidney and
heart studies
Prevents cell death mediated toxicities of multiple
chemotherapy agents (42, 43, 52)
PARylation of transcription
regulators
Promotes transcription In vitro thyroid cancer cell
lines
Upregulates NaI symporter transcription leading to
increased radio-iodine uptake in thyroid cancer (96)
Androgen receptor PARylation Increases androgen receptor
activity
In vivo and ex vivo prostate
cancer cells
Sensitizes prostate cancer to androgen depletion,
enhances effects of anti-androgen therapy, delays
onset of resistance to anti-androgen therapy (110)
ETS and EWS-FLI PARylation Promotes transcription of
target genes
In vivo and in vitro prostate
cancer and sarcoma cells
Cytotoxicity in ETS-prostate cancer and EWS-FLI
Ewing’s sarcoma specifically (14, 15)
Vimentin promoter PARylation Promotes transcription In vitro melanoma cells and
in vivo melanoma model
Inhibits cancer metastasis (63)
Interaction with VEGF, SDC-4,
PECAM1/CD31, HIF promoters
Promotes transcription In vitro endothelial cells Inhibits tumor angiogenesis (58–62)
cell cycle and proliferation (101). Increased AP-2 expression sup-
presses cancer cell growth (102) and may inhibit ras oncogene-
mediated transformation (101), effects likely diminished by PARP
inhibition (Figure 1). PARP-1 has also been shown to bind the
inhibitory element of COX-2, which mediates inflammation and
promotes VEGF-mediated pro-angiogenesis pathways activated in
cancer cells (103, 104).
Instances of PARP-1-mediated enzymatic activity affecting spe-
cific transcription factors or genes often translate to a clear role
for PARP-1 inhibitors as anticancer agents, even in monotherapy.
For example, ETS-positive prostate tumors and EWS-FLI-positive
Ewing’s sarcomas are highly sensitive to PARP inhibitors (14,
15). However, PARP-1 has multiple and diverse functions involv-
ing both PARylation activity and DNA-binding capability. Enzy-
matic inhibition, which decreases PARP-1 self PARylation, actually
increases DNA binding and may be detrimental in some cancers,
such as the malignant melanoma example given above. A greater
understanding of the relative effects of PARP-1 on transcriptional
activity is needed in order to select tumors with a molecular profile
conducive to pharmacologic inhibition through this mechanism.
SEX HORMONE SIGNALING
Sex hormones have been implicated in development, progres-
sion, and treatment sensitivity of prostate, breast, gynecologic, and
colon cancers. Sex steroid effects are mediated through their recep-
tors, which act as transcription factors in steroid-responsive tis-
sues. Any of the multiple levels of regulation controlling these sig-
naling pathways can become impaired, leading to abnormal prolif-
erative responses characteristic of cancer progression (Figure 1).
Similar to PARP-1-mediated regulation of transcription factor
activity, PARP-1 plays a role in regulating three of the sex hormone
receptors most commonly linked to cancer: estrogen receptor
(ER), progesterone receptor (PR), and androgen receptor (AR).
Approximately 80% of breast carcinomas are positive for ER,
identifying ER-targeted therapies as excellent, although not un-
failable, treatment options in these cancers (105). PARP-1 interacts
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with the ERa isoform both directly and through estradiol-induced
PARylation to enhance binding of ERa and other activating factors
to target gene promoters (106, 107), suggesting PARP inhibition
may enhance the activity of ER-targeted agents. A similar inter-
action occurs between PARP-1 and PR: PARP-1 binding of PR,
as well as hormone-activated CDK2-induced PR PARylation, acts
to stimulate cancer cell proliferation (108). PARP-1 regulation of
PR activity is of great interest in endometrioid carcinomas specif-
ically, as expression of PARP-1 and PR is positively correlated at
each pathologic stage of this cancer (109). However, the effects of
PARP inhibition in endometrial cancer have yet to be determined.
Recently, a report detailing the strong interaction between
PARP-1 and AR has generated much excitement over the potential
for PARP inhibitors in prostate cancer treatment. Human prostatic
adenocarcinoma, a cancer highly resistant to standard therapies,
is reliant on AR activity for growth and survival. Accordingly, AR-
targeted therapies are the primary treatment for these patients.
Unfortunately, there are multiple mechanisms for AR reactiva-
tion leading to tumor recurrence, a lethal phenotype known as
castration-resistant prostate cancer. PARP-1 enzymatic activity,
which is significantly upregulated in castration-resistant prostate
cancer, promotes both AR chromatin binding and transcription
factor functions. Although PARP-1 does localize with AR to reg-
ulatory sites of AR-target genes, the two proteins appear to be
members of separate complexes at these loci. Inhibition of PARP-
1 in vivo: (1) depletes both PARP-1 and AR at target genes, (2)
significantly reduces expression of target genes, including pro-
tumorigenic ets genes referenced previously, (3) sensitizes both
castration-resistant and castration-sensitive prostate cancer cells
to genotoxic insult and androgen depletion, (4) enhances the anti-
tumor effects of anti-androgen therapy, and (5) delays onset of
resistance to anti-androgen therapy. Ex vivo studies of castra-
tion resistance prostate tumors displayed a significant anti-tumor
response to both veliparib and olaparib, two well-known PARP
inhibitors, that correlates with reduced AR activity (110). These
results suggest PARP inhibitors have the potential to significantly
enhance existing prostate cancer therapy and improve outcomes
for patients with castration-resistant tumors.
PROMISE AND CHALLENGES
Poly(ADP-ribose) polymerase inhibitors are exciting new drugs
that are easily delivered, can be highly efficacious, and are asso-
ciated with few side effects. Mild nausea is commonly reported,
with rare instances of more serious symptoms such as temporary
cognitive deficits and myelosuppression. While ongoing clinical
trials are focused on exploiting the role of PARP-1 in DNA repair,
we have identified in this review multiple targetable functions
of PARP-1 that are not dependent on HR defects (Figures 1–4;
Table 1). One of the challenges in broadening the use of PARP
inhibitors in anticancer therapy is more efficient identification of
patients who may respond to these drugs. Some ongoing clinical
trials include analysis of protein expression – including HR pro-
teins, NF-κB, and PARP-1 itself – in relation to clinical response
in search for potential biomarkers of sensitivity. However, the list
of candidates is extensive and will continue to grow as additional
functions of PARP-1 are discovered. Banking tumor biopsies from
patients enrolled in PARP-1 clinical trials will greatly expedite the
development of a panel of biomarkers, as will increased use of
cancer genome sequencing and microarray technologies. Another
challenge will be in identifying and overcoming mechanisms of
resistance to PARP inhibition. For example, a second BRCA muta-
tion or a deletion of the original mutation can cause reversion
to HR-proficiency and resistance to PARP inhibitors in BRCA-
mutated cancers (111). As the majority of clinical applications
proposed here are theoretical or in pre-clinical development, asso-
ciated mechanisms of resistance are entirely unknown, although
development of such resistance is practically assured. Thirdly,
many of the functions discussed here are effected by PARP-1
binding rather than enzymatic activity. Currently available PARP
inhibitors act at the catalytic site of PARP-1, which does result in
some degree of altered binding capacity via changes in autoPARy-
lation status. However, treatment with PARP inhibitors may not
effectively inhibit specific PARP-1 interactions, or may require
different dosing. It will be important to study the various clini-
cally available agents to determine if, and to what extent, binding
domains are affected. Despite these obstacles, PARP inhibition is
an extremely promising anticancer strategy and, as the first agents
near completion of phase III trials, it will be exciting to see the
magnitude of impact PARP inhibitors will have in clinical practice.
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